| __timestamp | Ascendis Pharma A/S | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 79529000 |
| Thursday, January 1, 2015 | 9415000 | 91224000 |
| Friday, January 1, 2016 | 11504000 | 102413000 |
| Sunday, January 1, 2017 | 13482000 | 146987000 |
| Monday, January 1, 2018 | 25057000 | 213695000 |
| Tuesday, January 1, 2019 | 48473000 | 342000000 |
| Wednesday, January 1, 2020 | 76669000 | 661000000 |
| Friday, January 1, 2021 | 160180000 | 1283000000 |
| Saturday, January 1, 2022 | 221227000 | 2676000000 |
| Sunday, January 1, 2023 | 264410000 | 3297000000 |
| Monday, January 1, 2024 | 284545000 | 3790000000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Over the past decade, Genmab A/S and Ascendis Pharma A/S have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Genmab A/S consistently reported higher SG&A expenses, peaking at approximately 3.3 billion in 2023, a staggering 41-fold increase from 2014. In contrast, Ascendis Pharma A/S showed a more conservative growth in SG&A expenses, increasing from 6.3 million in 2014 to 264 million in 2023, a 42-fold rise. This data suggests that while both companies have expanded their operations, Genmab A/S has taken a more aggressive approach. Understanding these trends provides valuable insights into their strategic priorities and operational efficiencies, offering a glimpse into the financial dynamics of the biotech industry.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation